Effect of Eclipta alba and Ocimum sanctum on haloperidol induced parkinsonism

Chahal, Harmel Singh; Sharma, S.K.

doi:10.22270/jddt.v8i5.1871

Cited by 1 publication

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans, neuroleptics cause two distinct forms of motor disturbances, termed extrapyramidal side effects: tardive dyskinesia and catalepsy. 6 Dopamine D2 receptors can be blocked directly or indirectly, resulting in these symptoms. These unwanted effects are the principal detriment associated with the application of traditional neuroleptics in therapeutic settings.…”

Section: Discussionmentioning

confidence: 99%

“…Haloperidol is indicated for the treatment of psychotic disorders and their manifestations, such as hallucinations. 6 It has been connected to the inhibition of monoamine transport in the brain, specifically the cessation of impulse transmission in dopaminergic neurons. 7 Haloperidol, a commonly used neuroleptic for psychosis, is limited by its proclivity for causing extrapyramidal movement disorders, including tardive dyskinesia, akathisia, akinesia, dystonia, and Parkinsonism.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neuroprotective Effects of P-Coumaric Acid on Haloperidol-Induced Catalepsy Through Ameliorating Oxidative Stress and Brain Dopamine Level

Pathan

Jain

Kumawat

et al. 2022

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Objective To evaluate the effect of p-coumaric acid (p-CA) on haloperidol-induced catalepsy in Swiss albino male mice. Methods To induce catalepsy, haloperidol (1 mg/kg i.p.) was administered for 21 consecutive days. p-CA (50, 75, and 100 mg/kg, PO) was administered 30 min before haloperidol injection for 21 consecutive days. For catalepsy, locomotor activity and motor coordination scores were recorded on the 17, 14, and 21 days of drug treatment, while the gait analysis score was recorded on day 21. After behavioral testing, animals were sacrificed, and various biochemical and histopathology tests of the brain were conducted. Dopamine, malondialdehyde, reduced glutathione (GSH), superoxide dismutase (SOD), and catalase activity were examined in the brain. Results Chronic administration of haloperidol significantly increased catalepsy in mice. It also produced hypolocomotion, motor coordination, and gait disturbance in mice. p-CA significantly inhibited haloperidol-induced catalepsy. Haloperidol significantly increased malondialdehyde levels in the brain. While dopamine levels in the brain dropped along with GSH, SOD, and catalase activity levels, which also had an impact on the histology of the brain. p-CA significantly reduced haloperidol-induced increases in brain oxidative stress, dopamine levels in the brain, and brain histology in mice. Discussion p-CA significantly reduced haloperidol-induced catalepsy, possibly through reducing oxidative stress and increasing brain dopamine levels. It can be a good candidate drug for extrapyramidal symptoms in Parkinson’s disease and adjuvant therapy with antipsychotic drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%